Table of Contents Table of Contents
Previous Page  172 / 916 Next Page
Show Menu
Previous Page 172 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169

ineffective or cause side effects. Polymorphic variants of genes that

code CYP450 enzymes cause differences in their activity and there-

fore in efficacy and safety of drugs that are metabolized by them.

Aim of the study

Determine whether pharmacogenetic testing

of CYP2D6, CYP2C19 and CYP2C9 polymorphism would have had

influence on selected patients’ treatment courses.


Five patients that were diagnosed for treament-

resistant mood disorders in Vilnius university hospital Santariskiu

clinics centre of neurology, department of psychiatry were invited

to give blood samples for genetic testing retrospectively. Patients’

CYP2C19, CYP2D6 and CYP2C9 enzymes genetic polymorphism

results were compared with previous empirical pharmacological

treatment courses of these patients.


In four out of five cases significant polymorphism of

CYP2C19 enzyme allele was detected. In all of these cases 1*/2*

variant, that conditions intermediate metabolizer phenotype, was

identified. Alterations in CYP2D6 and CYP2C19 regions were not

found. In three cases the presence of varied genetic variant

could have been clinically relevant. In two of these cases Ser-

traline and valproates, that are both metabolized by CYP2C19

enzyme, were taken by patients and side effects were observed.

Unsuccessful treatment was repeated without effect, both in

clinical and outpatient environment. Continuous rehospitaliza-

tion took place until appropriate empirical treatments were



Pharmacogenetic testing could have had influence

on treatment choices for three out of five selected patients leading

to less side effects and rehospitalizations.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Mthfr Allele distribution in Romanian

schizophrenia patients

B. Nemes

, D. C


Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca,

Department of Medical Psychology, Cluj-Napoca, Romania

Corresponding author.


Currently available data on the aetiology of

schizophrenia suggests a major involvement of epigenetic mecha-

nisms. One such mechanism could be the alteration of activation

and silencing of genes, which involves DNA methylation and

de-methylation. The main limiting enzyme involved in the methyl-

donor cycle is methylene-tetra-hydro-folate-reductase (MTHFR),

and the most frequently observed mutation in the MTHFR gene,

altering its activity, is the C677 T mutation.


In the present study, we investigated the frequency of

MTHFR C677 T mutation and total plasma homocysteine (tHcy)

concentrations in a sample of Romanian schizophrenia patients as

compared to healthy controls.


Seventy schizophrenia patients (35% females) with a

mean age of 38.8


20.5 years and 50 healthy controls (50% females)

with a mean age of 36.3


11.6 years were included. MTHFR geno-

type was determined through polymerase chain reaction and tHcy

levels were determined through reversed phase high-pressure liq-

uid chromatography.


Schizophrenia patients, registered higher frequency

of the T allele, with the CC genotype observed in 39.4% of

them, as compared to a frequency of 60.6% in the control

group (


= 0.002–Fisher’s exact test). tHcy concentrations did

not differ between the two groups (10.7


4.2 vs. 11.2




> 0.005–Mann–Whitney U test).


Romanian schizophrenia patients have a signifi-

cantly higher frequency of theMTHFRC677 Tmutation, butwithout

significant effect on tHcy concentrations.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Influence of 5-HTR2C polymorphisms

on metabolic syndromes in Thai

schizophrenia patients

A. Puangpetch

1 ,

, C . N

a Nakorn

1 , W.


2 ,

C. Sukasem



Pathology service, Faculty of Medicine, Ramathibodi hospital,

Mahidol University, Bangkok, Thailand


Psychiatry, Somdet Chaopraya Institute of Psychiatry, Bangkok,


Corresponding author.


Metabolic syndrome is a significant problem in

the schizophrenia patients. Previous research demonstrated that

single nucleotide polymorphisms in the serotonin 2C receptor

(5HTR2C) genes are associated with metabolic syndrome related

to schizophrenia patients taking atypical anti-psychotic drugs.

This study aimed to investigate whether the effect of 3 SNPs in

5HTR2C gene on the presence of the metabolic syndrome in Thai

schizophrenia patients.


We conducted a cross-sectional study and 154 patients

were recruited. The schizophrenia patients were identified from a

diagnostic and statistical manual of mental disorders, 4th edition,

(DSM-IV) and criterion and determined the metabolic syndrome

according to the 2005 international diabetes federation (IDF)

Asia criteria. Patients were genotyped for the 5HTR2C rs51,8147,

rs126,881,02, rs128,367,71 polymorphisms.


The preliminary analysis from 154 patients showed the

metabolic syndrome prevalence was 38.73%, with 46.50% in male

and 53.48% in female patients. The results showed that the patients

who have heterozygous and homozygous variant on 5HTR2C gene

(rs518,147 and rs126,881,02) showed a significant difference in the

presence of metabolic syndrome when compare with patients who

carry homozygous wild type (


= 0.007), especially in male patients



= 0.002). The association between 5HTR2C polymorphisms and

metabolic syndrome was found in male patients but not found in

female patients.


These findings suggest that 5HTR2C genotypes are

associated with the metabolic syndrome in patients taking atypical

anti-psychotics. However, themetabolic syndrome results fromthe

multigenetic effects. The further studies should focus on the other

genes, which were involved in metabolic syndrome.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Prevalence of the CYP2D6*10 (C100 T)

polymorphism in psycho-neurological

patients in North-Western and

Siberian regions of the Russia

N.A. Shnayder

1 , R.F

. Nasyrova

2 , L.V

. Lipatova

3 ,

V.V. Teplyashina


, K.A. Sosina


, N.A. Sivakova

3 ,


E.N. Bochanova


, D.V. Dmitrenko


, I.P. Artyuhov



N.G. Neznanov



Voyno-Yasenetsky, the Department of Medical Genetics and Clinical

Neurophysiology, The Krasnoyarsk State medical University named

after Prof. V.F., Krasnoyarsk, Russia


The Department of Personalized Psychiatry and Neurology, St.

Petersburg Psychoneurological Research Institute named after V.M.

Bekhterev, Saint-Petersburg, Russia